The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
I am a molecular and cell biologist with a major research focus on haemopoiesis and leukaemia development. This work principally involves the analysis of mutant mouse models.
Nanomedicines Immunotargeting: Hitting The Target Or Lost In Translation ?
Funder
National Health and Medical Research Council
Funding Amount
$413,042.00
Summary
Nanomedicines are some of the most exciting novel approaches to improving the way we detect, manage and treat cancers. This cross-disciplinary project aims to provide a rigorous understanding of how nanomedicines penetrate solid tumour tissues. To validate in vitro tumour model developed in the project, in vivo studies will be carried out in a mice model. The penetration and distribution of nanomedicines inside tumour tissues after intravenous administration will be determined.
I am a structural biologist investigating the molecular control of cell death. Atomic resolution structural data are used to guide the discovery of new drugs.
Schistosomiasis is one of the world's most serious and prevalent diseases affecting nearly 200 million people world-wide. It is currently treated with a single drug, though there is growing concern about the development of resistance to it. In this proposal we will explore whether a new cellular pathway involving the cell death machinery we have identified in the disease-causing parasites could provide a possible target for the development of new treatments against schistosomiasis.
Molecular Characterisation Of The DBHS Proteins In Telomerase Assembly
Funder
National Health and Medical Research Council
Funding Amount
$686,246.00
Summary
Telomerase is an enzyme that is active in over 90% of cancers. Telomerase activity allows cancer cells to divide an indefinite number of times. We have identified a novel role for the DBHS protein family in regulating telomerase activity. We aim to investigate the mechanisms by which these proteins function to assemble and transport telomerase to its site of action in the cell. We then aim to develop chemical inhibitors of these proteins, and test their utility in preventing cancer cell growth.